Publications by authors named "M Mamta Sai"
Background: Disproportionately enlarged subarachnoid space hydrocephalus (DESH) is one of the neuroradiological characteristics of idiopathic normal pressure hydrocephalus (iNPH), which makes statistical analyses of brain images difficult. This study aimed to develop and validate methods of accurate brain segmentation and spatial normalisation in patients with DESH by using the Computational Anatomy Toolbox (CAT12).
Methods: Two hundred ninety-eight iNPH patients with DESH and 25 healthy controls (HCs) who underwent cranial MRI were enrolled in this study.
Occupational radiation exposure to the eye lens of medical staff during endoscopic retrograde cholangiopancreatography (ERCP) should be kept low so as not to exceed annual dose limits. Dose should be low to avoid tissue reactions and minimizing stochastic effects. It is known that the head and neck of the staff are exposed to more scattered radiation in an over-couch tube system than in a C-arm system (under-couch tube).
View Article and Find Full Text PDFArticle Synopsis
- The activation of nuclear retinoid X receptors (RXRs) involves releasing corepressors and recruiting coactivators, influencing gene activation or repression.
- Research identified a synthetic agonist that significantly increases the binding of PGC1α (a coactivator) to RXR, unlike the natural ligand 9-cis retinoic acid.
- The study produced three related RXR agonists with varying abilities to enhance PGC1α recruitment, suggesting potential new therapies through targeted RXR-PGC1α interactions via selective coregulator modulation.
The human tailless homologue receptor (TLX) is a ligand-activated transcription factor acting as a master regulator of neural stem cell homeostasis. Despite its promising potential in neurodegenerative disease treatment, TLX ligands are rare but required to explore phenotypic effects of TLX modulation and for target validation. We have systematically studied and optimized a TLX agonist scaffold obtained by fragment fusion.
View Article and Find Full Text PDFArticle Synopsis
- - Colorectal adenocarcinoma is the most common type of colorectal cancer in the U.S., driven by genetic mutations like APC, KRAS, HER-2 IHC3+, CHEK-2, and TP53 that result in cancer development.
- - Standard treatment for metastatic colorectal cancer often includes chemotherapy and targeted therapies, but many patients endure disease progression, prompting the search for new treatments like fruquintinib, a selective VEGFR inhibitor.
- - A case report describes a patient with metastatic colorectal cancer who suffered a cerebellar hemorrhage after starting fruquintinib, emphasizing the importance of close monitoring and personalized risk assessments for patients on this medication.